We are live on ! Find out more
PHS

PFM Health Sciences Portfolio holdings

AUM $1.1B
1-Year Est. Return 57.92%
This Fund
S&P 500
This Quarter Est. Return
+28.08%
1 Year Est. Return
+57.92%
3 Year Est. Return
+183.93%
5 Year Est. Return
+283%
10 Year Est. Return
+2,507.28%
AUM
$1.67B
AUM Growth
-$456M
Cap. Flow
-$727M
Cap. Flow %
-43.59%
Top 10 Hldgs %
45.69%
Holding
80
New
7
Increased
16
Reduced
26
Closed
17

Top Buys

Rank Stock Value
1
VRTX icon
Vertex Pharmaceuticals
VRTX
+$55M
2
UHS icon
Universal Health Services
UHS
+$15M
3
AVTR icon
Avantor
AVTR
+$13.9M
4
SYK icon
Stryker
SYK
+$13.1M
5
BSX icon
Boston Scientific
BSX
+$12.7M

Top Sells

Rank Stock Value
1
SGEN
Seagen Inc. Common Stock
SGEN
+$59.7M
2
CAH icon
Cardinal Health
CAH
+$55.5M
3
UNH icon
UnitedHealth
UNH
+$51.6M
4
BIIB icon
Biogen
BIIB
+$48M
5
IRTC icon
iRhythm Holdings
IRTC
+$45.8M

Sector Composition

Rank Sector Weight
1 Healthcare 96.63%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
VEEV icon
26
Veeva Systems
VEEV
$33.5B
$22.9M 1.37%
118,905
– –
ELV icon
27
Elevance Health
ELV
$83B
$22.5M 1.35%
47,681
+23,150
+94% +$10.7M
EPIX
28
DELISTED
ESSA Pharma
EPIX
$21.5M 1.29%
3,262,500
-936,753
-22% -$4.61M
INBX
29
DELISTED
Inhibrx, Inc. Common Stock
INBX
$20.4M 1.23%
537,964
+249,347
+86% +$5.34M
IMVT icon
30
Immunovant
IMVT
$7.91B
$19.9M 1.19%
472,540
– –
DAWN
31
DELISTED
Day One Biopharmaceuticals
DAWN
$19M 1.14%
1,303,575
-921,023
-41% -$11.2M
ACLX
32
DELISTED
Arcellx
ACLX
$18.6M 1.12%
335,198
+94,860
+39% +$4.28M
SYK icon
33
Stryker
SYK
$131B
$17.6M 1.05%
58,629
+46,523
+384% +$13.1M
AVTR icon
34
Avantor
AVTR
$9.25B
$15.4M 0.93%
+676,738
New +$13.9M
PRAX icon
35
Praxis Precision Medicines
PRAX
$8.52B
$14.6M 0.88%
656,548
+61,882
+10% +$1.11M
BSX icon
36
Boston Scientific
BSX
$70.2B
$13.8M 0.83%
+238,136
New +$12.7M
ZBH icon
37
Zimmer Biomet
ZBH
$18.8B
$13.7M 0.82%
+112,656
New +$12.6M
ROIV icon
38
Roivant Sciences
ROIV
$24.1B
$13.6M 0.82%
1,215,033
– –
HOWL icon
39
Werewolf Therapeutics
HOWL
$17.9M
$13.4M 0.8%
3,468,177
+909,895
+36% +$2.32M
SNDX icon
40
Syndax Pharmaceuticals
SNDX
$1.7B
$12.9M 0.77%
595,523
-2,119,712
-78% -$32.6M
UNH icon
41
UnitedHealth
UNH
$377B
$10.2M 0.61%
19,361
-96,706
-83% -$51.6M
XENE icon
42
Xenon Pharmaceuticals
XENE
$6.02B
$8.88M 0.53%
192,856
+114,269
+145% +$4.04M
ADAP
43
DELISTED
Adaptimmune Therapeutics
ADAP
$8.27M 0.5%
10,423,135
– –
ISRG icon
44
Intuitive Surgical
ISRG
$133B
$8.2M 0.49%
24,307
-147,736
-86% -$44M
SANA icon
45
Sana Biotechnology
SANA
$885M
$7.68M 0.46%
1,883,337
+639,198
+51% +$2.35M
PRTA icon
46
Prothena Corp
PRTA
$436M
$6.9M 0.41%
189,744
-646,827
-77% -$24.9M
ERAS icon
47
Erasca
ERAS
$6.19B
$5.49M 0.33%
2,575,511
-1,355,122
-34% -$2.86M
OM icon
48
Outset Medical
OM
$92.5M
$5.41M 0.32%
+66,617
New +$5.42M
PMVP icon
49
PMV Pharmaceuticals
PMVP
$59.7M
$4.57M 0.27%
1,473,013
+177,909
+14% +$471K
IOBT
50
DELISTED
IO Biotech
IOBT
$4.4M 0.26%
2,341,107
+987,654
+73% +$1.18M
1
2
3 4

Similar funds

DAM
Delta Asset Management Memphis, Tennessee $1.1B AUM 14.89% 1-Year Est. Return
MAM
Mark Asset Management New York $1.1B AUM 43.79% 1-Year Est. Return
LCM
Legato Capital Management San Francisco, California $1.1B AUM 61.65% 1-Year Est. Return
DAM
DLD Asset Management New York $1.1B AUM 4.68% 1-Year Est. Return
KCM
Khrom Capital Management Miami Beach, Florida $1.09B AUM 14.82% 1-Year Est. Return
CF
Corebridge Financial Houston, Texas $1.09B AUM 1.85% 1-Year Est. Return
MIA
MMBG Investment Advisors Miami, Florida $1.09B AUM 30.96% 1-Year Est. Return
YL
YCG LLC Austin, Texas $1.1B AUM 4.87% 1-Year Est. Return

PFM Health Sciences's Q4 2023 Portfolio in Review

As of Q4 2023, PFM Health Sciences held 80 positions worth $1.67B, down 21% from $2.12B the previous quarter. Its ten largest holdings account for 46% of the portfolio.

PFM Health Sciences withdrew a net $727M in Q4 2023, closing 17 positions and reducing 26 holdings. Its most notable exit was Seagen Inc. Common Stock, an estimated $59.7M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 97% of assets, up from 96% a quarter earlier.

Against the trend, PFM Health Sciences opened a new position in Vertex Pharmaceuticals worth $60.6M.

  • PFM Health Sciences's largest Q4 2023 buy was Vertex Pharmaceuticals: 148,852 shares worth $60.6M.
  • PFM Health Sciences added most to Universal Health Services in Q4 2023, an estimated $15M increase.
  • PFM Health Sciences's biggest Q4 2023 reduction was UnitedHealth, cutting an estimated $51.6M.
  • PFM Health Sciences fully exited Seagen Inc. Common Stock in Q4 2023, selling an estimated $59.7M.
  • PFM Health Sciences's ten largest holdings make up 46% of its $1.67B portfolio in Q4 2023.
  • PFM Health Sciences opened 7 new positions and closed 17 in Q4 2023.
  • PFM Health Sciences's portfolio value fell 21% quarter-over-quarter to $1.67B.

Based on PFM Health Sciences's 13F filing for Q4 2023, filed 14 Feb 2024.